Home » BioNTech, Fosun Pharma Vaccinate Patients in New Phase 1 Chinese Study
BioNTech, Fosun Pharma Vaccinate Patients in New Phase 1 Chinese Study
Germany-based BioNTech and Fosun Pharma have begun a phase 1 trial of their COVID-19 vaccine candidate in China.
The trial will include a total of 144 patients, who will either receive two 10-microgram or 30-microgram doses of the messenger RNA-based vaccine candidate BNT162b1 or a placebo.
BioNTech is supplying the vaccine for the China trial from its manufacturing facilities in Europe.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May